Bristol-Myers Squibb Co. v. Merck & Co., Inc.
1:15-cv-00560
📡 5G SEP • ETSI DeclaredOverview
Parties
Defendant
Bristol-Myers Squibb Co. Operating Company
Represented By
12 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Akin Gump Strauss Hauer & Feld LLP
1735 Market Street, Ste 12th Floor
Merck Sharp & Dohme Corp. Operating Company
Represented By
4 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Merck & Co., Inc. Operating Company
Represented By
17 Attorneys ListedMcCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Ashby & Geddes
Ashby & Geddes, 500 Delaware Avenue, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
McCarter & English, LLP
Renaissance Centre, 405 N. King Street, 8th Floor
Plaintiff
Dana-Farber Cancer Institute, Inc. Operating Company
Represented By
0 Attorneys ListedTasuku Honjo NPE (Individual / Inventor)
Represented By
4 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Akin Gump Strauss Hauer & Feld LLP
1735 Market Street, Ste 12th Floor
E.R. Squibb & Sons L.L.C. Operating Company
Represented By
4 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Akin Gump Strauss Hauer & Feld LLP
1735 Market Street, Ste 12th Floor
Ono Pharmaceutical Co., Ltd Operating Company
Represented By
4 Attorneys ListedFarnan LLP
919 North Market Street, 12th Floor
Farnan LLP
919 North Market Street, 12th Floor
Akin Gump Strauss Hauer & Feld LLP
1735 Market Street, Ste 12th Floor
Respondent
Dr. Clive Wood NPE (Individual / Inventor)
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 7 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 9,067,999 B1 Asserted | US Continuation / Sibling | View Official Patent → |
| 🇯🇵 Japan | JP 2002194491 | Japan Counterpart | View Official Patent → |
| 🇯🇵 Japan | JP 2003029846 | Japan Counterpart | View Official Patent → |
| 🌐 PCT International (WIPO) | WO 2004004771 A1 | PCT World Application | View Official Patent → |
| 🇺🇸 United States | US 8,168,179 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,728,474 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,402,899 B2 | US Continuation / Sibling | View Official Patent → |
Merck Sharp & Dohme Corp. v. Ono Pharmaceutical Co., Ltd.
Merck Sharp & Dohme Corp. v. Ono Pharmaceutical Co., Ltd.
Merck Sharp & Dohme Corp. v. Ono Pharmaceutical Co., Ltd.
Merck Sharp & Dohme Corp. v. Ono Pharmaceutical Co., Ltd.
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP • ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US9067999
Immunopotentiative composition
|
Filed: 2015-03-04
Issued: 2015-06-30
|
Active (8.3 yrs remaining)
Expires: 2035-03-04
|
|
|
US8728474
Immunopotentiative composition
|
Filed: 2010-12-02
Issued: 2014-05-20
|
Expired (Term Ended)
Expires: 2025-10-02
|
|
|
US9073994
Immunopotentiative composition
|
Filed: 2014-11-21
Issued: 2015-07-07
|
Active (8.0 yrs remaining)
Expires: 2034-11-21
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).
Procedural Motions & Interlocutory Orders
Total Motions
39
Dispositive
14
Granted
0
Denied
0
Pending / Review
23
Motions by Category
Key Dispositive Motions & Rulings